Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012;2:a006148.

Article  PubMed  PubMed Central  Google Scholar 

Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168–74.

Article  PubMed  Google Scholar 

Polderman TJ, Benyamin B, de Leeuw CA, Sullivan PF, van Bochoven A, Visscher PM, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nat Genet. 2015;47:702–9.

Article  CAS  PubMed  Google Scholar 

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.

Article  PubMed  Google Scholar 

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gau SY, Lai JN, Yip HT, Wu MC, Wei JC. Higher dementia risk in people with gastroesophageal reflux disease: a real-world evidence. Front Aging Neurosci. 2022;14:830729.

Article  PubMed  PubMed Central  Google Scholar 

Adewuyi EO, O’Brien EK, Nyholt DR, Porter T, Laws SM. A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer’s disease and gastrointestinal tract disorders. Commun Biol. 2022;5:691.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bunnage ME, Gilbert AM, Jones LH, Hett EC. Know your target, know your molecule. Nat Chem Biol. 2015;11:368–72.

Article  CAS  PubMed  Google Scholar 

Yao Z, van Velthoven CTJ, Nguyen TN, Goldy J, Sedeno-Cortes AE, Baftizadeh F, et al. A taxonomy of transcriptomic cell types across the isocortex and hippocampal formation. Cell. 2021;184:3222–41.e26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bakken TE, Jorstad NL, Hu Q, Lake BB, Tian W, Kalmbach BE, et al. Comparative cellular analysis of motor cortex in human, marmoset and mouse. Nature. 2021;598:111–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sebastiani G, Morissette C, Lagacé C, Boulé M, Ouellette MJ, McLaughlin RW, et al. The cAMP-specific phosphodiesterase 4B mediates Abeta-induced microglial activation. Neurobiol Aging. 2006;27:691–701.

Article  CAS  PubMed  Google Scholar 

Bales KR, Plath N, Svenstrup N, Menniti FS. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer’s disease. In: Dominguez C, editor. Neurodegenerative diseases. Topics in medicinal chemistry. Vol. 6; Berlin, Heidelberg: Springer; 2010. pp. 57–90.

García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem Neurosci. 2012;3:832–44.

Article  PubMed  PubMed Central  Google Scholar 

Kametani F. Phosphodiesterase as a drug target of Alzheimer’s disease. Austin Alzheimers J Parkinsons Dis. 2015;2:1021.

Google Scholar 

Wu Y, Li Z, Huang YY, Wu D, Luo HB. Novel phosphodiesterase inhibitors for cognitive improvement in Alzheimer’s disease. J Med Chem. 2018;61:5467–83.

Article  CAS  PubMed  Google Scholar 

Nabavi SM, Talarek S, Listos J, Nabavi SF, Devi KP, Roberto de Oliveira M, et al. Phosphodiesterase inhibitors say NO to Alzheimer’s disease. Food Chem Toxicol. 2019;134:110822.

Article  CAS  PubMed  Google Scholar 

Tibbo AJ, Tejeda GS, Baillie GS. Understanding PDE4’s function in Alzheimer’s disease; a target for novel therapeutic approaches. Biochem Soc Trans. 2019;47:1557–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanders O, Rajagopal L. Phosphodiesterase inhibitors for Alzheimer’s disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimers Dis Rep. 2020;4:185–215.

Article  PubMed  PubMed Central  Google Scholar 

Xi M, Sun T, Chai S, Xie M, Chen S, Deng L, et al. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer’s disease. Eur J Med Chem. 2022;232:114170.

Article  CAS  PubMed  Google Scholar 

Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest. 2004;114:1624–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer’s disease. J Neurosci. 2005;25:8898–902.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cong YF, Liu FW, Xu L, Song SS, Shen XR, Liu D, et al. Rolipram ameliorates memory deficits and depression-like behavior in APP/PS1/tau triple transgenic mice: involvement of neuroinflammation and apoptosis via cAMP signaling. Int J Neuropsychopharmacol. 2023;26:585–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng H, Wang C, He W, Wu X, Li S, Zeng Z, et al. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects. Metab Brain Dis. 2019;34:583–91.

Article  CAS  PubMed  Google Scholar 

Wang H, Zhang FF, Xu Y, Fu HR, Wang XD, Wang L, et al. The phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer’s disease: a preclinical study in APP/PS1 transgenic mice. Int J Neuropsychopharmacol. 2020;23:700–11.

Article  PubMed  PubMed Central  Google Scholar 

Guo H, Cheng Y, Wang C, Wu J, Zou Z, Niu B, et al. FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects. Neuropharmacology. 2017;116:260–9.

Article  CAS  PubMed  Google Scholar 

Sierksma AS, van den Hove DL, Pfau F, Philippens M, Bruno O, Fedele E, et al. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology. 2014;77:120–30.

Article  CAS  PubMed  Google Scholar 

Ricciarelli R, Brullo C, Prickaerts J, Arancio O, Villa C, Rebosio C, et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer’s disease. Sci Rep. 2017;7:46320.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGirr A, Lipina TV, Mun HS, Georgiou J, Al-Amri AH, Ng E, et al. Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition. Neuropsychopharmacology. 2016;41:1080–92.

Article  CAS  PubMed  Google Scholar 

Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci. 2014;17:661–3.

Article  CAS  PubMed  Google Scholar 

Sasaguri H, Hashimoto S, Watamura N, Sato K, Takamura R, Nagata K, et al. Recent advances in the modeling of Alzheimer’s disease. Front Neurosci. 2022;16:807473.

Article  PubMed  PubMed Central  Google Scholar 

Al-Amri AH, Armstrong P, Amici M, Ligneul C, Rouse J, El-Asrag ME, et al. PDZD8 disruption causes cognitive impairment in humans, mice, and fruit flies. Biol Psychiatry. 2022;92:323–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dawson N, Ferrington L, Lesch KP, Kelly PA. Cerebral metabolic responses to 5-HT2A/C receptor activation in mice with genetically modified serotonin transporter (SERT) expression. Eur Neuropsychopharmacol. 2011;21:117–28.

Article  CAS  PubMed  Google Scholar 

Hughes RB, Whittingham-Dowd J, Clapcote SJ, Broughton SJ, Dawson N. Altered medial prefrontal cortex and dorsal raphé activity predict genotype and correlate with abnormal learning behavior in a mouse model of autism-associated 2p16.3 deletion. Autism Res. 2022;15:614–27.

Article  PubMed  PubMed Central  Google Scholar 

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.

Article  PubMed  PubMed Central  Google Scholar 

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Statist Soc B. 1995;57:289–300.

Google Scholar 

Sakakibara Y, Sekiya M, Saito T, Saido TC, Iijima KM. Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis. BMC Neurosci. 2018;19:46.

Article  PubMed  PubMed Central  Google Scholar 

Nieraad H, de Bruin N, Arne O, Hofmann MCJ,